MedTrace Logo

COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies

NCT04776005 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-01-03

No results posted yet for this study

Summary

In the context of malignant disease, it is likely that vaccine efficacy and immunogenicity depends on the type of pathology, stage of the disease, immunosuppression induced by the treatments, in addition to more classic factors such as age, general condition and possibly the type of vaccine used.

There are very little data on the efficacy and immunogenicity of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with malignant disease in the active phase of treatment.

This multicenter observational study aims to assess the efficacy and the immunogenicity of anti-Sars-CoV-2 vaccines in the cohort of patients treated for malignant pathology (solid or hematological tumors) at Saint Louis Hospital and in thoracic oncology patients at Bichat Hospital.

Conditions

  • Solid Tumor
  • Hematologic Malignancy
  • Thoracic Cancer
  • Cancer, Treatment-Related
  • Vaccine Response Impaired

Interventions

OTHER

Data collection

Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Luis TEIXEIRA, MD, PhD · Breast Disease Unit, Saint-Louis Hospital, APHP, Université de Paris, INSERM U976

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-22
Primary Completion
2024-02-29
Completion
2024-02-29

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04776005 on ClinicalTrials.gov